Cardinal Health Names New Chief Executive, Posts Mixed Q4 Earnings

Comments
Loading...
  • Cardinal Health Inc CAH has reported Q4 FY22 adjusted EPS of $1.05, up 36% Y/Y, missing the consensus of $1.17.
  • Sales increased 11% to $47.1 billion, beating the consensus of $44.71 billion.
  • Revenue from the pharmaceutical segment increased 13% to $43.3 billion, driven primarily by branded pharmaceutical sales growth from large Pharmaceutical Distribution and Specialty customers.
  • The medical segment sales decreased 11% to $3.8 billion due to the divestiture of the Cordis business and lower products and distribution volumes.
  • Medical segment loss reached $(16) million primarily due to net inflationary impacts and global supply chain constraints in products and distribution. 
  • Management Change: Cardinal has elected Jason Hollar, current CFO, as the next CEO of the company, effective September 1, succeeding Mike Kaufmann.
  • Patricia English will serve as the Interim CFO.
  • Outlook: Cardinal Health expects FY23 adjusted EPS of $5.05-$5.40 compared to the consensus of $5.37.
  • The company targets a Medical segment profit of at least $650 million by FY25.
  • Price Action: CAH shares are down 3.19% at $60.75 during the premarket session on the last check Thursday.
Market News and Data brought to you by Benzinga APIs
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise

Posted In:
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!